The initiation of early ADME screening dramatically decreases the proportion of compounds failing in clinical trials. Our preclinical ADME screening services help customers eliminate weak drug candidates prior to clinical development, thereby helping them to focus their resources on potential drug candidates so that the right drugs get to the right patients faster and more efficiently.
Read our fact sheet to learn how IQVIA Laboratories’ high-throughput ADME screening services can accelerate your preclinical studies.
Download Document
Related Insights
ADME Services
Accelerating your drug discovery, preclinical and clinical programs
Developing Assays for Novel Drugs
Current science regarding hybrid assays, why they are considered the next "big thing," the technical challenges, and the regulatory impact of these assays.
Hybrid Assays for Protein Bioanalysis
Combining immuno-affinity with liquid chromatography-mass spectrometry (LC-MS)
Absolute Bioavailability Analysis Using Stable Isotopes
A Liquid Chromatography-Tandem Mass Spectrometry Approach
Bioanalysis for Immuno Oncology with Mike Brown
I-O clinical development podcast series
High Throughput ADME Testing
Minimizing turnaround time for ADME assays
Bioanalytical & ADME Laboratory Services
Accelerate and enhance your discovery, preclinical and clinical programs
ADME Services
Accelerating your drug discovery, preclinical and clinical programs with ADME services
Assay Development for Large-Scale Clinical Studies
Bioanalytical expertise to support large-scale, international studies
Early Hit-to-Lead ADME Screening Bundle
Bundled Screening Assays to Accelerate Candidate Selection in Drug Discovery
